Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 28Terminated 5

Sponsor Class

OTHER 6INDUSTRY 5NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Mesothelioma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × nintedanib × Clear all
NCT02231164 2025-02-13

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Boehringer Ingelheim

Phase 3 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02780700 2025-02-03

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Boehringer Ingelheim

Phase 2 Terminated
1 enrolled 5 charts
Gastrointestinal

Colorectal Neoplasms

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

NCT02751385 2019-03-14

Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 5 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡